Introduction
============

COPD is a common lung disease characterized by variable day-to-day respiratory symptoms. Management is aimed at both improving symptom control and preventing or reducing exacerbations.[@b1-copd-12-059] Inhalers deliver medication directly to the lungs and many types of inhaler devices are available. Different devices may require unique inhalation techniques to ensure the medication is delivered optimally.[@b2-copd-12-059] For example, metered-dose inhalers (MDIs) require a slow and steady inhalation for adequate lung deposition.[@b3-copd-12-059],[@b4-copd-12-059] In contrast, inhalation when using dry-powder inhalers (DPIs) must be quick to disaggregate and dispense the powder and deliver the required dose.[@b4-copd-12-059],[@b5-copd-12-059] Further variations exist, in the dose-loading mechanisms of inhalers (device preparation) and in the resistance to airflow within the device. There is also a negative impact of exhaling into the device after priming, which impacts drug delivery for some but not all devices.[@b6-copd-12-059] With such precision required, it is not surprising that errors in inhalation technique are common and can lead to reduced effectiveness of treatment.[@b7-copd-12-059]--[@b13-copd-12-059] Incorrect inhalation technique is well-recognized as a problem with patients using only one inhaler, and it could be compounded when introducing additional inhalers into a treatment regimen. Use of multiple inhalers compared to single inhalers has been shown to have an adverse effect on outcomes, even without consideration of inhalation technique.[@b14-copd-12-059],[@b15-copd-12-059]

Despite suggestions that mixing devices could be detrimental to patient outcomes,[@b2-copd-12-059] no one has yet investigated its real impact in COPD. For such a common illness, with high mortality and significantly impaired quality of life,[@b16-copd-12-059],[@b17-copd-12-059] it is important for research to highlight where problems lie, to allow management guidelines to be addressed accordingly.

This study used real-life observational data to compare and quantify the COPD outcomes for two types of patient -- those who use multiple inhaler devices with similar inhalation technique and those who use multiple inhaler devices with mixed inhalation techniques.

Materials and methods
=====================

Data source and permissions
---------------------------

For this study, data from the Optimum Patient Care Research Database (OPCRD)[@b18-copd-12-059] -- a primary care database containing anonymized, routinely-recorded clinical data from over 2 million patients -- were used. The data originated from over 550 General Practices (GPs) across the UK and was supplemented by patient-completed questionnaire data for approximately 10% of patients with asthma and COPD. The OPCRD has ethical approval from the National Health Service Research Authority to hold and process anonymized research data (Research Ethics Committee reference: 15/EM/0150). This study was conducted to standards recommended for observational research[@b19-copd-12-059] and was approved by the Anonymized Data Ethics Protocols and Transparency committee -- the independent scientific advisory committee for the OPCRD; patient consent was not required due to the retrospective nature of this study, as approved by this committee. This study is registered with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.[@b20-copd-12-059]

Study design
------------

A historical, matched cohort study design was used, creating two study cohorts that differed in terms of the inhaler devices used by patients. The two cohorts were classified after an additional COPD therapy was prescribed to patients, via a separate inhaler device. Prior to this additional prescription, if patients used more than one device, these multiple devices required similar inhalation technique. After the additional prescription, patients were allocated to either the "similar-devices cohort", where patients used two or more inhalers that required similar inhalation technique or the "mixed-devices cohort", where the patients used two or more inhalers, with at least one inhaler requiring a largely different inhalation technique compared to their other device(s). For the main analysis, the inhalers were categorized as "similar" if they were all aerosols (MDI or a soft mist inhaler) or all DPIs. A patient using any combination of these two categories would be allocated to the "mixed-devices" cohort. Hence, a patient using at least one MDI alongside at least one DPI was allocated to the "mixed-devices" category.

To investigate the impact of a more stringent categorization, a sensitivity analysis was also carried out. Here, the DPIs were distinguished further and devices were considered "mixed" if they varied by the level of resistance to airflow through the device or by the number of doses that can be loaded into the device (ie, single dose versus multiple dose). [Table 1](#t1-copd-12-059){ref-type="table"} shows the specific categorization of devices for each type of analysis.

This study consisted of two continuous years of data, within the period 2008--2015, on either side of an index date. The index date was identified as the point at which a prescription of additional COPD therapy was made, which required the use of an inhaler device separate from the current COPD treatment of that patient. The year preceding this date was the baseline year and the subsequent year was the outcome year. Study cohorts ("similar" versus "mixed") were matched in a ratio of 1:1 to minimize differences that could affect the comparison of study outcomes. Matching variables were identified through comparison of baseline variables between unmatched cohorts and by assessing the variables that were most predictive of COPD outcome (number of exacerbations).

Inclusion and exclusion criteria
--------------------------------

Patient records were subject to the following inclusion criteria: record of diagnosis of COPD; at least 40 years of age at the date of initial prescription; an initial prescription of COPD therapy, including short-acting beta agonist (SABA), short-acting muscarinic agonist (SAMA), long-acting beta agonist (LABA) or long-acting muscarinic agonist, which could be given alone or in combination, but must be given in "similar" devices if in combination; one or more prescriptions of additional COPD therapy via a separate inhaler device, on the index date or during the outcome year (a change in inhaler device, rather than the addition of a device, does not fall under the inclusion criteria); at least 2 years of continuous medical records from GP (at least 1 year of which is when patient is on initial therapy and 1 year on additional therapy).

Patients were excluded if they had "mixed" devices prior to the index date or if they had at least one prescription for nebulizer prior to the index date, as this is another category of device altogether.

Outcome measures
----------------

The primary outcome was the rate of moderate/severe COPD exacerbations[@b21-copd-12-059] during the outcome year, comparing the similar-devices cohort to the mixed-devices cohort. Details of exacerbation criteria are summarized in the notes of [Table 2](#t2-copd-12-059){ref-type="table"}. The comparison of exacerbation rates was done by estimating an adjusted incidence rate ratio (IRR) -- adjusted by factors that were not used in the matching process but were found to be different between cohorts at baseline. A secondary outcome was the average daily SABA use during the outcome year, which was compared between study cohorts. A proportional odds ratio (OR) was estimated, comparing the odds of being in higher SABA dose categories. Again, this was adjusted by important factors that differed at baseline.

Statistical analysis
--------------------

Summary statistics were computed for baseline characteristics of study cohorts, including demographic variables, COPD-related characteristics and therapies, comorbidities and co-medications. Variables found to be significantly different between cohorts (*P*\<0.05) were potentially used as adjusting variables for the primary and secondary analyses. If these variables were found to be unimportant in the multivariate models for the primary/secondary outcomes, they were removed to arrive at the most parsimonious model. Confounders were checked for co-linearity using Spearman's correlation coefficients for linear relationships, and plots and univariate logistic regression models for non-linear relationships. If colinearity was observed between several adjusting variables in the primary and secondary multivariate models, the most significant of the variables was retained in the model. Through this process, all available adjusting variables that impacted the unadjusted results were included. Summary statistics were also computed for COPD outcomes, that is the number of exacerbations and average daily SABA use.

The primary analysis fitted a negative binomial regression model to estimate the IRR for rate of exacerbations, with 95% confidence intervals (CIs). A conditional, fixed effects version of this model was applied to adjust for confounders and account for overdispersion in the data.

For the secondary analysis, average daily SABA use during the outcome year was calculated as follows: $$\frac{\text{Number~of~inhalers}*\text{dpses~per~inhaler}}{365} \times \text{dosage}\left( {\mu g} \right)$$

This was grouped into five categories with cutoff points chosen using quintiles. This strengthened the model used to investigate the secondary outcome by ensuring adequate numbers of patients in each category. The model used was an ordinal logistic regression model to estimate the proportional OR (with 95% CI) of being prescribed a higher average daily SABA drug dosage, comparing the similar-devices cohort to the mixed-devices cohort. Standard errors were adjusted by appropriate confounders.

The aforementioned primary and secondary analyses were repeated for the sensitivity analysis mentioned previously, where the matched cohorts were based on an alternative categorization of devices. A further sensitivity analysis was carried out on a subgroup of the study sample, as determined by the COPD treatment received during the outcome year. Patients were categorized according to the combination of therapy received, for example, LABA ± SAMA ± SABA, and inhaled corticosteroids (ICS) ± SAMA ± SABA. The largest group was analyzed separately to investigate whether the effect found in the main analysis remained in this subgroup.

The level of statistical significance was set at 5% (ie, *P*\<0.05). No prospective power calculation was carried out since the sample size was determined by the number of eligible patients in the OPCRD according to the inclusion criteria and by the number who could then be matched exactly to a patient in the opposite cohort. All categorization and coding of variables, and definition of COPD-related variables, were approved by the steering committee. Analyses were carried out using IBM SPSS Statistics version 22 and Stata version 14.

Results
=======

Patients
--------

After applying inclusion and exclusion criteria, 71,517 patients with COPD were identified from the OPCRD. This number was reduced to 52,378 following removal of duplicates and of records with missing observations for the matching variables. The chosen matching variables were age, sex, body mass index (BMI), smoking status, forced expiratory volume in 1 second (FEV~1~) % predicted, number of moderate/severe exacerbations during baseline year, number of types of COPD treatment, having active asthma and index year. After 1:1 matching, there were 8,225 patients in each study cohort ([Figure 1](#f1-copd-12-059){ref-type="fig"}). For the alternative categorization of devices, ([Table 1](#t1-copd-12-059){ref-type="table"}) there were 7,545 patients in each matched cohort.

Patients in both cohorts had a mean age of 67 years (SD ≈10), with the majority (71.3%) aged between 61 and 80 years ([Table 2](#t2-copd-12-059){ref-type="table"}). Just over half were males (56.5%), mean BMI was 27.4 (SD ≈6) and 36.8% were current smokers at the time of index date. In the baseline year, mean FEV~1~ % predicted was \~56 (SD ≈23) and 51.4% of patients had zero moderate or severe exacerbations, while 7.7% had 3 or more exacerbations.

During the baseline year, 17.5% of patients in the similar-devices cohort and 18.9% in the mixed-devices cohort required one course of acute oral corticosteroids (OCS) ([Table 3](#t3-copd-12-059){ref-type="table"}). Equivalent percentages for at least one course of antibiotics with a lower respiratory consultation were 21.9% and 21.3%. Over half of patients in each cohort required at least one COPD-related consultation. The majority of patients in each cohort were receiving only one medication type of COPD treatment (53.2%), and 40% were receiving two types. Here, medication type refers to the type of COPD therapy, whether inhaled (eg, SABA and ICS) or in tablet form (eg, theophylline and mucolytes). Comparison between cohorts showed statistically significant differences, in that more patients in the mixed-devices cohort needed; at least one acute OCS course; three or more antibiotics courses; higher SABA inhaler usage per day and at least one COPD-related consultation, during the baseline year. Due to these significant differences, which could be interpreted as an increased likelihood of exacerbation in the mixed-devices cohort, acute course of OCS, course of antibiotics, SABA use and COPD-related consultations were investigated as potential adjusting variables in the primary outcome model.

Information about patient comorbidities, baseline co-medications and other measures of COPD severity is given in [Table S1](#SD4-copd-12-059){ref-type="supplementary-material"}. Significant differences (in percent) between matched cohorts were found in patients with rhinitis (less in mixed-devices cohort), eczema (less in mixed-devices cohorts), osteoporosis (more in mixed-devices cohorts) and pneumonia (more in mixed-devices cohorts). These comorbidities, as well as statin-taking (more prevalent in mixed-devices cohort), were investigated as potential adjusting variables in the main analysis. Significant differences were also observed for modified Medical Research Council dyspnea scale score and Global initiative for chronic Obstructive Lung Disease classification, but neither of these was used as a matching or adjusting variable due to the number of missing observations. Specific combinations of COPD treatment during the baseline year are given in [Table S2](#SD5-copd-12-059){ref-type="supplementary-material"}.

Primary outcome
---------------

The number of moderate/severe exacerbations during the outcome year declined in both cohorts with respect to the baseline year, with 58.5% of patients in the similar-devices cohort and 53.4% in the mixed-devices cohort, having zero exacerbations in the outcome year ([Table 4](#t4-copd-12-059){ref-type="table"}). After adjustment by confounders, including course of antibiotics, asthma diagnosis and paracetamol use, the rate of exacerbations was lower in the similar-devices cohort compared with the mixed-devices cohort, with an IRR of 0.82 (95% CI 0.80--0.84; [Figure 2](#f2-copd-12-059){ref-type="fig"}).

Secondary outcome
-----------------

During the outcome year, 18.9% of patients in the similar-devices cohort and 26.4% in the mixed-devices cohort used \>550 µg SABA per day ([Table 4](#t4-copd-12-059){ref-type="table"}). In general, patients in the similar-devices cohort were less likely to be in a higher SABA dose group compared to mixed-devices cohort, with an adjusted proportional OR of 0.54 (95% CI 0.51--0.57; [Figure 2](#f2-copd-12-059){ref-type="fig"}).

Sensitivity analyses
--------------------

The first sensitivity analysis was carried out on study cohorts that were based on an alternative categorization of inhaler devices -- one that included differences in DPIs (n=7,545 in each cohort). The similar-devices cohort based on DPI use was further categorized into DPIs which were single-dose capsule products, DPIs with medium resistance and DPIs with medium to high and high resistance (as classified by Laube et al[@b4-copd-12-059]). Results for the primary outcome were similar to the main analysis, with the similar-devices cohort showing a reduced rate of moderate/severe exacerbations compared to the mixed-devices cohort (IRR 0.82, 95% CI 0.78--0.86; [Figure S1](#SD1-copd-12-059){ref-type="supplementary-material"}). Results for the secondary analysis showed the same effect as in the main analysis, but with slightly weaker magnitude: similar-devices cohort was less likely to be in a higher category of average SABA dose per day during the outcome year (OR 0.61, 95% CI 0.57--0.64).

The second sensitivity analysis was applied to the largest subgroup of COPD treatment combination during the outcome year, which was ICS ± LABA ± SAMA ± SABA ([Table S3](#SD6-copd-12-059){ref-type="supplementary-material"}). This subgroup consisted of 3,680 patients in the similar-devices cohort (44.7% of the total patients) and 2,859 patients in the mixed-devices cohort (34.8% of the total patients). Again, the rate of moderate/severe exacerbations was reduced in the similar-devices cohort compared with the mixed-devices cohort but to a lesser extent than in the main analysis (IRR 0.90, 95% CI 0.82--0.99; [Figure S2](#SD2-copd-12-059){ref-type="supplementary-material"}). There was also a weaker effect than the main analysis on odds of being in a higher group of daily SABA dose, though it was still significant in favor of similar-devices cohort (OR 0.70, 95% CI 0.64--0.76).

Combining both sensitivity analyses, that is, the largest treatment combination subgroup after the alternative categorization of devices, led to similar results ([Figure S3](#SD3-copd-12-059){ref-type="supplementary-material"}).

Discussion
==========

This study demonstrates that patients with COPD who were prescribed inhalers requiring similar inhalation technique to the inhalers they were already using had better COPD outcomes than patients whose additional inhalers required a different technique. Specifically, patients using similar devices had a lower rate of exacerbations and were less likely to use higher doses of SABA medication, suggesting better symptom control. This effect was present after matching/adjustment of important patient characteristics and common predictors of future exacerbations.

There is a wide range of inhalers for COPD on the market, and no pharmaceutical company manufactures all types of available inhaled treatment. This leads to inhaler devices requiring different inhalation techniques. Previous literature has hypothesized that mixing inhaler devices could cause confusion and have an adverse effect on patient outcomes in COPD and asthma.[@b2-copd-12-059] The main finding of the current study is consistent with this hypothesis and with a recent asthma study that had a similar research question comparing patients whose reliever and controller devices were both breath-actuated inhalers (BAIs) to patients with BAI as controller and MDI as reliever.[@b22-copd-12-059] They found that the patients with only BAIs were more likely to achieve asthma control during 1 year of follow-up than the patients with different inhalers. The current results are also consistent with studies showing that simpler treatment regimens are more effective in COPD. Large observational studies by Yu et al[@b14-copd-12-059] and Chrischilles et al[@b15-copd-12-059] found that patients using multiple inhaler devices, rather than a single device, had increased hospital resource utilization and number of exacerbations. Although the cohorts in the current study were comparable in terms of number of devices, the trend toward simplicity is common in both scenarios.

The most likely reason for reduced effectiveness in patients with mixed devices is that the variation in inhalation technique leads to inhalation errors. Suboptimal inhalation results in medication not being delivered to the target area adequately. In a study involving asthma and COPD patients, inhaler errors were associated with several adverse outcomes, including hospitalization.[@b23-copd-12-059] Errors may be more common in specific types of patient. For example, MDIs require good coordination to ensure actuation coincides with (slow) inhalation. In contrast, although DPIs are breath-actuated, they require rapid and forceful inhalation. Additionally, errors have been shown to increase with age.[@b23-copd-12-059],[@b24-copd-12-059] As respiratory function is reduced in older people, this may impact the ability to effectively use a DPI. MDI use may also be affected with increasing age due to reduced hand strength to correctly push the inhaler. However, cohorts in the current study were well matched in terms of age and comorbidity, so it is likely that common errors would be present in both cohorts, whether devices were mixed or not. Instead, a possible explanation to the observed difference between mixed-devices and similar-devices cohorts is that as errors are common when using one type of device, there may be even more errors when there are several types of device in use.

The main analysis suggested that patients using all MDI or all DPI devices have better outcomes; the study then went further by considering specific types of DPI. This distinction may be more meaningful from the patient perspective, particularly with regard to dose preparation. For example, multi-dose DPIs have a mechanism that must be rotated to load the medication and so is an additional method of use that must be learned even if the patient is familiar with single-dose DPIs. The current study results showed that the impact on COPD outcomes for this alternative categorization of devices was similar to the main analysis. This suggests that the essential differences between types of DPI may be as important as the more obvious differences between MDIs and DPIs and could act as a barrier to correct inhaler use. Differences in general could also act as a barrier to patient adherence, in turn reducing effectiveness. More complex treatment regimens may be off-putting to patients. For example, a study by Yu et al[@b25-copd-12-059] found that patients using multiple inhalers were less likely to be adherent than those using a single inhaler.

The current study observed an 18% reduction in exacerbation rate when inhalers with similar techniques were used and observed that 41%--45% of patients in either cohort had at least one moderate/severe exacerbation during the outcome year. This 18% reduction, even if modest, is important in relieving the burden on the COPD patient population. Further, it will have an impact on the high health care costs.[@b26-copd-12-059]

The strength of this study is that it analyzed a large sample from a high-quality database, representative of the real-life COPD patient population. Randomized controlled trials (RCTs) often study a highly selected patient sample and the results cannot necessarily be extrapolated to the general patient population; this makes observational studies an essential contribution to evidence.[@b27-copd-12-059] Further, in contrast to RCTs where the length of follow-up is often limited, this study obtained 1-year follow-up data, which could capture relatively infrequent events such as exacerbations. Likewise, baseline characteristics were not based on a cross-sectional view from a specified date, but on 1 year of baseline data from multiple index dates to form comparable cohorts.

We addressed the main drawback of an observational study, such as lack of randomization, by applying population matching to the study design and adjustment for confounders to analyses. This was especially important as the baseline comparisons showed that patients in the mixed-devices cohort (though the devices were not mixed during the baseline period) appeared to be less controlled than those in the similar-devices cohort. Without allowing for these initial differences, the comparison of outcomes would be biased. To allow this, confounding was minimized as much as possible by adjusting statistical models by factors such as COPD severity and comorbidities. This was also important as the study sample, by definition, were patients whose symptoms were increasing to the point where additional treatment was required (ie, the index date). Number of treatment types was also used as a matching variable; an imbalance here could have caused bias in terms of adherence. Relevant sensitivity analyses were carried out to test the robustness of the main results. This included subgroup analysis in the largest treatment combination group, which confirmed that the main effect was not being driven by less common treatment combinations.

Limitations of the current study include the possibility of residual confounding, which may be present despite the measures described earlier. An unmeasured confounder that may have introduced bias is any cognitive disorder in the patients. This is relevant in an intervention that depends on knowing how to use multiple devices. However, this bias will have been reduced somewhat when allowing for age and co-medications. This study did not take into account specific types of medication, which may be a source of bias. Salbutamol, for example, is used frequently in reliever MDIs, whereas controller medications are more diverse. This is something to be considered in future studies.

This study did not capture information about patient adherence or about specific errors in inhaler use. Such data may have offered a useful insight, as these factors may drive the effect on outcomes. It was considered outside the scope of the primary research question in this study; however, it may be of interest to investigate adherence in future studies, especially with evidence suggesting variation in level of adherence between types of device.[@b28-copd-12-059] A further limitation of this study is that patients were not distinguished within cohorts by their device type, that is, the proportion of patients in the similar-devices cohort using only DPIs or only MDIs is unknown. This may have led to differences between cohorts if it was the case that the mixed-devices cohort had a much larger proportion of DPI users than the similar-devices cohort. Differences could arise due to variation in adherence levels or inhaler errors made with increasing age, as mentioned previously.

There have already been calls for more careful consideration to be given to the choice of prescribed inhaler devices in COPD.[@b29-copd-12-059] The Aerosol Drug Management Improvement Team suggested a strategy in 2011,[@b29-copd-12-059] which offered physicians guidelines for various aspects of COPD management, including choice of inhaler. A previous study found that physicians usually base inhaler choices on the age, skills and physical capacity of their patients.[@b30-copd-12-059] The current study provides evidence to suggest that prescribing inhalers that require similar inhalation technique should be a further consideration when choosing additional therapies.

Conclusion
==========

After being prescribed one or more additional inhaler devices, COPD patients who used multiple devices that required similar inhalation techniques had more favorable clinical outcomes in comparison with patients who used devices that required mixed inhalation techniques. This relationship existed after controlling for likely confounders, suggesting that mixing devices may inherently lead to incorrect use and/or reduced patient adherence. This is an intuitive result, consistent with numerous sources in the literature. However, similar studies on different data sets would be useful in order to consolidate evidence and support recommendations in primary care management.

Supplementary materials
=======================

###### 

Effect of similar versus mixed devices on primary and secondary COPD outcomes -- alternative categorization of devices.

**Notes:** ^a^IRR adjusted by COPD consultations, use of antibiotics, statins and paracetamol. OR adjusted by SABA dosage, use of statins, beta-blockers and paracetamol. n=7,545 in each cohort, for this categorization of devices.

**Abbreviations:** CI, confidence interval; SABA, short-acting beta agonist.

###### 

Effect of similar versus mixed devices on primary and secondary COPD outcomes -- largest treatment combination subgroup.

**Notes:** ^a^IRR adjusted by antibiotics courses, asthma diagnosis and use of paracetamol. OR adjusted by SABA dosage, use of statins, beta-blockers and paracetamol. n=3,680 (44.7%) in similar-devices cohort and n=2,859 (34.8%) in mixed-devices cohort.

**Abbreviations:** CI, confidence interval; SABA, short-acting beta agonist.

###### 

Effect of similar versus mixed devices on primary and secondary COPD outcomes -- alternative categorization of devices and largest treatment combination subgroup.

**Notes:** ^a^IRR adjusted by antibiotics courses, asthma diagnosis and use of paracetamol. OR adjusted by SABA dosage, use of statins, beta-blockers and paracetamol. n=3,762 (49.9%) in similar-devices cohort and n=2,577 (34.2%) in mixed-devices cohort.

**Abbreviations:** CI, confidence interval; SABA, short-acting beta agonist.

###### 

Comorbidities, baseline co-medications and COPD classifications in each study cohort

  Patient characteristics                                                                                      n (%)          *P*-value[e](#tfn17-copd-12-059){ref-type="table-fn"}   
  ------------------------------------------------------------------------------------------------------------ -------------- ------------------------------------------------------- ------------
  **Comorbidities**                                                                                                                                                                   
  Asthma[a](#tfn13-copd-12-059){ref-type="table-fn"}                                                           1,870 (22.7)   1,926 (23.4)                                            0.17
  Asthma (active)[a](#tfn13-copd-12-059){ref-type="table-fn"},[c](#tfn15-copd-12-059){ref-type="table-fn"}     896 (10.9)     896 (10.9)                                              NA
  Diabetes[a](#tfn13-copd-12-059){ref-type="table-fn"}                                                         1,388 (16.9)   1,356 (16.5)                                            0.487
  Oral thrush[b](#tfn14-copd-12-059){ref-type="table-fn"}                                                      49 (0.6)       63 (0.8)                                                0.187
  Rhinitis[a](#tfn13-copd-12-059){ref-type="table-fn"}                                                         677 (8.2)      584 (7.1)                                               0.006
  Rhinitis (active)[b](#tfn14-copd-12-059){ref-type="table-fn"},[d](#tfn16-copd-12-059){ref-type="table-fn"}   345 (4.2)      331 (4.0)                                               0.579
  Eczema[a](#tfn13-copd-12-059){ref-type="table-fn"}                                                           1,162 (14.1)   1,143 (13.9)                                            0.665
  Eczema (active)[b](#tfn14-copd-12-059){ref-type="table-fn"},[d](#tfn16-copd-12-059){ref-type="table-fn"}     223 (2.7)      181 (2.2)                                               0.034
  Cardiovascular disease[a](#tfn13-copd-12-059){ref-type="table-fn"}                                           2,811 (34.2)   2,817 (34.3)                                            0.918
  Heart failure[a](#tfn13-copd-12-059){ref-type="table-fn"}                                                    409 (5.0)      404 (4.9)                                               0.918
  Ischemic heart disease[a](#tfn13-copd-12-059){ref-type="table-fn"}                                           1,693 (20.6)   1,719 (20.9)                                            0.605
  Hypertension[b](#tfn14-copd-12-059){ref-type="table-fn"}                                                     1,247 (15.2)   1,192 (14.5)                                            0.223
  Gastroesophageal reflux disease[a](#tfn13-copd-12-059){ref-type="table-fn"}                                  586 (7.1)      586 (7.1)                                               .0.99
  GERD (active)[b](#tfn14-copd-12-059){ref-type="table-fn"},[d](#tfn16-copd-12-059){ref-type="table-fn"}       400 (4.9)      419 (5.1)                                               0.49
  Osteoporosis[a](#tfn13-copd-12-059){ref-type="table-fn"}                                                     451 (5.5)      512 (6.2)                                               0.038
  Pneumonia[b](#tfn14-copd-12-059){ref-type="table-fn"}                                                        75 (0.9)       113 (1.4)                                               0.006
  Anxiety, depression                                                                                          373 (4.5)      381 (4.6)                                               0.763
  Charlson comorbidity index score[b](#tfn14-copd-12-059){ref-type="table-fn"}                                                                                                        
   0                                                                                                           5,610 (68.2)   5,657 (68.8)                                            0.477
   1--4                                                                                                        1,756 (21.4)   1,736 (21.1)                                            
   5--9                                                                                                        318 (3.9)      334 (4.1)                                               
   ≥ 10                                                                                                        541 (6.6)      498 (6.1)                                               
  **Co-medications**                                                                                                                                                                  
  NSAIDs[c](#tfn15-copd-12-059){ref-type="table-fn"}                                                           3,368 (41.0)   3,474 (42.2)                                            0.087
  Paracetamol[c](#tfn15-copd-12-059){ref-type="table-fn"}                                                      3,129 (38.0)   3,229 (39.3)                                            0.103
  Beta blockers[c](#tfn15-copd-12-059){ref-type="table-fn"}                                                    1,080 (13.1)   1,016 (12.4)                                            0.127
  Statins[c](#tfn15-copd-12-059){ref-type="table-fn"}                                                          2,518 (30.6)   2,640 (32.1)                                            0.027
  **Other measures of COPD severity**                                                                                                                                                 
  mMRC score (closest to index date)                                                                                                                                                  \<0.001
   Non-missing                                                                                                 6,572 (79.9)   6,654 (80.9)                                            
   0--1                                                                                                        3,863 (58.8)   3,765 (56.6)                                            
   ≥ 2                                                                                                         2,709 (41.2)   2,889 (43.4)                                            
  GOLD grade (closest to index date)                                                                                                                                                  Not tested
   Non-missing                                                                                                 7,726 (93.9)   7,791 (94.7)                                            
   A                                                                                                           717 (9.3)      717 (9.2)                                               
   B                                                                                                           4,796 (62.1)   4,788 (61.5)                                            
   C                                                                                                           1,903 (24.6)   1,918 (24.6)                                            
   D                                                                                                           310 (4.0)      368 (4.7)                                               

**Notes:**

With a diagnostic code recorded at any time prior to or at the last extraction date;

calculated for the baseline period including the last extraction date;

asthma patients exclude those with asthma resolved codes;

includes prescriptions to treat the comorbidity within the baseline period and at the last extraction date;

*P*-values are from conditional logistic regression models; GOLD grade was not compared between cohorts as there was a large amount of missing data.

**Abbreviations:** mMRC, modified Medical Research Council; GOLD, Global initiative for chronic Obstructive Lung Disease -- groups based on 2015 GOLD Strategy; GERD, gastroesophageal reflux disease; NSAIDs, non-steroidal anti-inflammatory drugs; NA, not applicable (as variable was used for matching).

###### 

Combinations of COPD therapy during baseline year in each study cohort

  Inhaler therapy                   n (%)          
  --------------------------------- -------------- --------------
  SABA                              3,839 (46.7)   3,775 (45.9)
  SAMA + SABA                       1,075 (13.1)   1,105 (13.4)
  LABA ± SAMA ± SABA                228 (2.8)      209 (2.5)
  LAMA ± SAMA ± SABA                243 (3.0)      194 (2.4)
  LABA + LAMA ± SAMA ± SABA         8 (0.1)        3 (0.0)
  ICS ± SAMA ± SABA                 2,271 (27.6)   2,150 (26.1)
  ICS + LABA ± SAMA ± SABA          511 (6.2)      757 (9.2)
  ICS + LAMA ± SAMA ± SABA          8 (0.1)        1 (0.0)
  LTRA ± SAMA ± SABA                17 (0.2)       17 (0.2)
  LABA + LTRA ± SAMA ± SABA         1 (0.0)        0 (0.0)
  ICS + LTRA ± SAMA ± SABA          17 (0.2)       7 (0.1)
  ICS + LABA + LTRA ± SAMA ± SABA   7 (0.1)        7 (0.1)

**Abbreviations:** SAMA, short-acting muscarinic agonist; SABA, short-acting beta agonist; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist.

###### 

Combinations of COPD therapy during outcome year in each study cohort

  Inhaler therapy                          n (%)          
  ---------------------------------------- -------------- --------------
  LABA ± SAMA ± SABA                       604 (7.3)      336 (4.1)
  LAMA ± SAMA ± SABA                       471 (5.7)      1,136 (13.8)
  LABA + LAMA ± SAMA ± SABA                51 (0.6)       250 (3.0)
  ICS ± SAMA ± SABA                        2,464 (30.0)   653 (7.9)
  ICS + LABA ± SAMA ± SABA                 3,680 (44.7)   2,859 (34.8)
  ICS + LAMA ± SAMA ± SABA                 90 (1.1)       498 (6.1)
  ICS + LABA + LAMA ± SAMA ± SABA          780 (9.5)      2,358 (28.7)
  LABA + LTRA ± SAMA ± SABA                0 (0.0)        2 (0.0)
  LAMA + LTRA ± SAMA ± SABA                4 (0.1)        3 (0.0)
  ICS + LTRA ± SAMA ± SABA                 12 (0.2)       3 (0.0)
  ICS + LAMA + LTRA ± SAMA ± SABA          4 (0.1)        3 (0.0)
  ICS + LABA + LAMA + LTRA ± SAMA ± SABA   11 (0.1)       48 (0.6)
  ICS + LABA + LTRA ± SAMA +/i SABA        53 (0.6)       76 (0.9)
  Others                                   1 (0.0)        0 (0.0)

**Abbreviations:** SAMA, short-acting muscarinic agonist; SABA, short-acting beta agonist; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist.
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![Flow diagram showing study cohorts derived from Optimum Patient Care Research Database.\
**Notes:** ^a^Matching variables included are as follows: age, sex, body mass index, smoking status, forced expiratory volume in 1 second % predicted, number of moderate/severe exacerbations during baseline year, number of types of COPD treatment, active asthma and index year. Matching variables were derived from exploratory analysis of 1 year of baseline data.](copd-12-059Fig1){#f1-copd-12-059}

![Effect of similar versus mixed devices on primary and secondary COPD outcomes.\
**Notes:** ^a^IRR adjusted by antibiotic course, asthma diagnosis and paracetamol use. OR adjusted by baseline SABA and osteoporosis.\
**Abbreviations:** CI, confidence interval; SABA, short-acting beta agonist.](copd-12-059Fig2){#f2-copd-12-059}

###### 

Device categorization used to form study cohorts

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Categorization of devices[a](#tfn1-copd-12-059){ref-type="table-fn"}                                                                                                                                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  **Aerosols:** manual-activated MDI, manual-activated MDI with spacer, breath-actuated MDI and soft mist inhaler (pMDIs, CFC-free inhalers, breath-actuated inhalers, Clenil modulite, pMDIs + pacer, Autohaler, Easibreathe, Respimat)                                                       **Aerosols:** same as in main analysis

  **DPIs:** single-dose capsule DPI (Breezhaler, Aerolizer, Handihaler), multi-dose DPI with medium resistance (Accuhaler \[Diskus\], Novolizer, Genuair, Elipta) and multi-dose DPI with medium--high or high resistance (Turbohaler, Clickhaler, Pulvinal, Twisthaler, Easyhaler, Duoresp)   **Single-dose capsule DPI** (Breezhaler, Aerolizer, Handihaler)\
                                                                                                                                                                                                                                                                                               **Multi-dose DPI with medium resistance**: (Accuhaler \[Diskus\], Novolizer, Genuair, Ellipta)\
                                                                                                                                                                                                                                                                                               **Multi-dose DPI with medium--high or high resistance** (Turbohaler, Clickhaler, Pulvinal, Twisthaler, Easyhaler, Duoresp)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Devices from within categories (identified with headings in bold) are considered "similar" and devices from more than one category are considered "mixed".

**Abbreviations:** DPI, dry-powder inhaler; MDI, metered dose inhaler; pMDI, pressurized metered dose inhaler.

###### 

Baseline demographic characteristics and COPD severity of study cohorts

  Patient characteristics                                         Similar-devices cohort (n=8,225)   Mixed-devices cohort (n=8,225)
  --------------------------------------------------------------- ---------------------------------- --------------------------------
  **Demographic characteristics**                                                                    
  Age (years)                                                                                        
   40--60, n (%)                                                  1,856 (22.6)                       1,856 (22.6)
   61--80, n (%)                                                  5,863 (71.3)                       5,863 (71.3)
   \>80, n (%)                                                    506 (6.2)                          506 (6.2)
   Mean (SD)                                                      67.3 (9.9)                         67.2 (9.7)
  Male, n (%)                                                     4,645 (56.5)                       4,645 (56.5)
  Body mass index (kg/m^2^)                                                                          
   \<18.5, n (%)                                                  151 (1.8)                          151 (1.8)
   18.5--24.9, n (%)                                              2,892 (35.2)                       2,892 (35.2)
   25--29.9, n (%)                                                2,981 (36.2)                       2,981 (36.2)
   ≥30, n (%)                                                     2,201 (26.8)                       2,201 (26.8)
  Mean (SD)                                                       27.4 (6.1)                         27.4 (5.7)
  Smoking status (closest to index date)                                                             
   Nonsmoker, n (%)                                               584 (7.1)                          584 (7.1)
   Current smoker, n (%)                                          3,029 (36.8)                       3,029 (36.8)
   Ex-smoker, n (%)                                               4,612 (56.1)                       4,612 (56.1)
  **COPD severity**                                                                                  
  FEV~1~% predicted[a](#tfn4-copd-12-059){ref-type="table-fn"}                                       
  GOLD 1: FEV~1~ ≥80 (mild), n (%)                                717 (8.7)                          717 (8.7)
   GOLD 2: 50≤ FEV~1~ \<80 (moderate), n (%)                      4,659 (56.6)                       4,659 (56.6)
   GOLD 3: 30≤ FEV~1~ \<50 (severe), n (%)                        2,003 (24.4)                       2,003 (24.4)
   GOLD 4: FEV~1~ \<30 (very severe), n (%)                       846 (10.3)                         846 (10.3)
   Mean (SD)                                                      55.9 (22.6)                        55.7 (22.5)
  COPD exacerbations[b](#tfn5-copd-12-059){ref-type="table-fn"}                                      
   0, n (%)                                                       4,226 (51.4)                       4,226 (51.4)
   1, n (%)                                                       2,394 (29.1)                       2,394 (29.1)
   2, n (%)                                                       972 (11.8)                         972 (11.8)
   ≥3, n (%)                                                      633 (7.7)                          633 (7.7)

**Notes:** Variables were not compared statistically as all were used in matching process.

FEV~1~ % predicted grouped by GOLD classifications;

moderate/severe exacerbations were identified by acute course of oral corticosteroids (OCS) unlikely to be maintenance therapy, antibiotics prescribed within a lower respiratory consultation or admission to hospital/emergency department for COPD or following lower respiratory consultation. Further details of prescriptions of OCS and antibiotics are found in [Table 3](#t3-copd-12-059){ref-type="table"}.

**Abbreviations:** SD, standard deviation; FEV~1~, forced expiratory volume in 1 second; GOLD, Global initiative for chronic Obstructive Lung Disease.

###### 

Baseline COPD-related therapy of study cohorts

  COPD-related therapies                                                                                n (%)          *P*-value[a](#tfn7-copd-12-059){ref-type="table-fn"}   
  ----------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------------ ---------
  Acute oral corticosteroid (OCS) courses[b](#tfn8-copd-12-059){ref-type="table-fn"}                                                                                          0.019
   0                                                                                                    6,010 (73.1)   5,882 (71.5)                                           
   1                                                                                                    1,437 (17.5)   1,557 (18.9)                                           
   2                                                                                                    489 (6.0)      487 (5.9)                                              
   ≥3                                                                                                   289 (3.5)      299 (3.6)                                              
  Antibiotic courses with a lower respiratory consultation[c](#tfn9-copd-12-059){ref-type="table-fn"}                                                                         0.031
   0                                                                                                    5,111 (62.1)   5,205 (63.3)                                           
   1                                                                                                    1,803 (21.9)   1,755 (21.3)                                           
   2                                                                                                    782 (9.5)      725 (8.8)                                              
   ≥3                                                                                                   529 (6.4)      540 (6.6)                                              
  Number of types of COPD treatment                                                                                                                                           NA
   1                                                                                                    4,374 (53.2)   4,374 (53.2)                                           
   2                                                                                                    3,289 (40.0)   3,289 (40.0)                                           
   3                                                                                                    545 (6.6)      545 (6.6)                                              
   4                                                                                                    17 (0.2)       17 (0.2)                                               
  SABA inhaler usage (µg per day)                                                                                                                                             \<0.001
   0                                                                                                    735 (8.9)      839 (10.2)                                             
   1--55                                                                                                2,174 (26.4)   1,896 (23.1)                                           
   55--165                                                                                              1,927 (23.4)   1,959 (23.8)                                           
   165--440                                                                                             1,560 (19.0)   1,588 (19.3)                                           
   \>440                                                                                                1,829 (22.2)   1,943 (23.6)                                           
  COPD-related consultations                                                                                                                                                  \<0.001
   0                                                                                                    3,532 (42.9)   3,257 (39.6)                                           
   1                                                                                                    2,476 (30.1)   2,501 (30.4)                                           
   ≥2                                                                                                   2,217 (27.0)   2,467 (30.0)                                           

**Notes:**

*P*-values are from conditional logistic regression models.

All acute OCS courses that are definitely not maintenance therapy and/or all courses where dosing instructions suggest exacerbation treatment (eg, a reducing dose or a fixed term specified) and/or all courses with no dosing instructions, but unlikely to be maintenance therapy due to prescription strength or frequency of prescriptions.

Lower respiratory consultation refers to lower respiratory diagnostic codes (including asthma, COPD and LRTI Read codes), or asthma/COPD review codes excluding any monitoring letter codes, or lung function and/or asthma monitoring, and any additional respiratory examinations, referrals, chest X-rays, or events. ^b,c^Where \>1 OCS course/antibiotic prescription occurred within 2 weeks of each other, these events were considered to be the result of the same course. NA indicates that no comparison was done as variable was used for matching.

**Abbreviations:** LRTI, lower respiratory tract infection; SABA, short-acting beta agonist.

###### 

COPD outcomes in each study cohort during the outcome year

  COPD outcome                                                                 n (%)          
  ---------------------------------------------------------------------------- -------------- --------------
  Number of exacerbations                                                                     
   0                                                                           4,810 (58.5)   4,389 (53.4)
   1                                                                           1,985 (24.1)   2,004 (24.4)
   2                                                                           828 (10.1)     959 (11.7)
   3+                                                                          602 (7.3)      873 (10.6)
  Average daily SABA dosage[a](#tfn11-copd-12-059){ref-type="table-fn"} (µg)                  
   0                                                                           1,437 (17.5)   524 (6.4)
   \<110                                                                       1,742 (21.2)   1,698 (20.6)
   111--300                                                                    1,706 (20.7)   1,847 (22.5)
   301--550                                                                    1,788 (21.7)   1,984 (24.1)
   \>550                                                                       1,552 (18.9)   2,172 (26.4)

**Notes:**

Average daily SABA dosage grouped by quintiles, according to similar-devices cohort.

**Abbreviation:** SABA, short-acting beta agonist.
